Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2646)	11/2/2009 11:17:52 AM
From: Jibacoa	Respond to of 3722

In spite of the lower revenues and higher losses in the last 4Qs, the persistent insider selling and higher EL for the current Yr, VRTX opened with an UG and is having an spike today.<g> The stock was up 15.25% at its intraday H but is up only 13.89% at present.<g> bigcharts.marketwatch.com It has presented mid-stage results of its hepatitis C drug telaprevir,which is being developed with JNJ, at a conference. The preliminary results indicate that the drug might work just as well given BID as TID, as it had been tested, which would make the drug more convenient to use.Some analysts have said that the results had "exceeded expectations".<g> VRTX was one of the companies that have tried to exploit computer-aided drug design.<g> The stock has a god amount of resistance at the $41 to $45 level.<g> bigcharts.marketwatch.com Bernard